MOUNT PLEASANT, Mich., Nov. 9 /PRNewswire/ -- Dendritic Nanotechnologies Inc. (DNT), a company focused on the discovery, development, and commercialization of dendrimer technologies to create a new generation of innovative products for the identification and treatment of human diseases, has been awarded the “Advanced Medical Applications Technology Innovation of the Year” Award by a leading global growth consulting company. The Award was bestowed on DNT by Frost & Sullivan for its work in developing and commercializing the Priostar(TM) family of dendrimers.
Frost & Sullivan selected DNT from a field of several dozen nanotech companies. After a selection process that included primary participant interviews and extensive primary and secondary research, Frost & Sullivan concluded that DNT’s dendrimer-based nanostructures “represent a potent delivery platform for a vast array of diagnostics and therapeutics and could be employed to manufacture a variety of biotechnology and pharmaceutical products.”
Of particular importance during the evaluation process was the precise control over size, composition, surface functionality and interior space offered by the Priostar family of dendrimers. Precise control of their physical characteristics means that Priostar dendrimers can be tailored to a wide array of markets, including medical and health, food and agriculture, energy and electronics, environmental and industrial safety, personal and household, and chemicals and manufacturing.
Frost & Sullivan also noted that: “While nanotechnology in general has promised great advances, there are relatively few tangible products with clear and present applications. Moreover, many of these products cannot be cost-effectively produced in large enough volumes. DNT’s dendritic nanostructures appear to be an exception. These dendritic polymers can serve as effective delivery vehicles in vitro and in vivo due to their specific, precise and predictable architecture.”
“DNT’s Priostar dendrimers, as nanoscale building blocks, radically change the current economics of nanotechnology and we are pleased to see them validated by a prestigious growth consulting company such as Frost & Sullivan,” said Robert Berry, DNT’s chief executive officer. “Priostar has established a new price point for an essential technology, placing it within reach of new applications and uses.”
About Frost & Sullivan
Frost & Sullivan, a global growth consulting company, has been partnering with clients to support the development of innovative strategies for more than 40 years. The company’s industry expertise integrates growth consulting, growth partnership services, and corporate management training to identify and develop opportunities. Frost & Sullivan serves an extensive clientele that includes Global 1000 companies, emerging companies, and the investment community by providing comprehensive industry coverage that reflects a unique global perspective and combines ongoing analysis of markets, technologies, econometrics, and demographics. For more information, visit www.frost.com.
About DNT
Dendritic Nanotechnologies Inc. (DNT) is focused on the discovery, development, and commercialization of dendrimer technologies to create a new generation of innovative products for the identification and treatment of human diseases. DNT’s proprietary dendrimer platform serves as a targeted diagnostic and therapeutic delivery system for a wide variety of drugs to cancer cells and other diseases. Improved efficacy, enhanced solubility, and lower toxicity have been demonstrated for many existing drugs. DNT is committed to producing commercially viable dendrimers that can be manufactured in large quantities, and to driving down manufacturing complexity and costs. The company has a patent pending on its Priostar(TM) family of dendrimers, a novel dendrimer family that breaks through previous cost and manufacturing barriers.
DNT’s technology development is directed by Donald A. Tomalia, Ph.D., president and chief technical officer. Dr. Tomalia is the inventor of dendrimers and has led numerous commercial developments during a 25-year management and senior scientist career with The Dow Chemical Company. See www.dnanotech.com.
Starpharma is an equity holder in DNT and is focused on the development and application of dendrimer nanotechnologies as drugs against major diseases. Starpharma’s lead dendrimer product, VivaGel(TM) is currently in U.S. FDA Phase II human clinical trials. VivaGel is a topical microbicide gel product that has been developed for women as a preventative against the sexual transmission of HIV.
NOTE: STARBURST and Priostar are trademarks of Dendritic Nanotechnologies Inc. All other trademarks mentioned herein are held by their respective owners.
Dendritic Nanotechnologies Inc.
CONTACT: Tim Cox of Zing Public Relations, +1-650-369-7784 (office), or+1-650-888-6116 (cell), or tim@zingpr.com, for Dendritic NanotechnologiesInc.
Web site: http://www.dnanotech.com/
